DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Robert C, Ribas A, Wolchok JD. et al.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A Randomised dose-comparison cohort of a phase 1 trial.
Lancet (London, England) 2014;
384: 1109-1117
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.